24.71
+2.07%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Collegium Pharmaceutical
From its filings with the US Securities and Exchange Commission
Collegium Pharmaceutical is based in Stoughton, Massachusetts and is incorporated in Virginia. Its shares trade on Nasdaq under the ticker COLL. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $780.6m and net income of $62.9m. At that date it held total assets of $1.66bn and shareholders' equity of $301.7m.
Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (“ADHD”) and moderate to severe pain. We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the “Nucynta Products”), and Symproic, in the United States.
On September 3, 2024, we acquired Ironshore, which had developed and obtained commercial approval to market Jornay PM in the United States.
Jornay PM is a central nervous system (“CNS”) stimulant prescription medicine that contains methylphenidate HCl, a Schedule II methylphenidate, which was approved by the U.S. Food and Drug Administration (“FDA”) in August 2018 for the treatment of ADHD in people six years of age and older and currently the only FDA-approved stimulant medication that is dosed in the evening.
The acquisition of Ironshore expands our business beyond pain management and establishes a commercial presence in neuropsychiatry via the ADHD market.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 May 2015
- Employees
- 423
- Website
- collegiumpharma.com ↗
- Head office
- 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072
- Incorporated in
- VA
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Gino SantiniIndependent Chairman of the Board$362,023
- Mr. Vikram KarnaniPresident, Chief Executive Officer, Director, since 2024$10.8m
- Ms. Colleen TupperChief Financial Officer, Executive Vice President$3.2m
- Mr. Dean PatrasChief People Officer
- Mr. David DieterExecutive Vice President, General Counsel, Corporate Secretary
- Mr. Scott DreyerExecutive Vice President, Chief Commercial Officer$2.8m
- Ms. Jane GonnermanExecutive Vice President - Strategy and Corporate Development
- Dr. Thomas SmithExecutive Vice President, Chief Medical Officer$2.5m
- Dr. Rita Balice-GordonIndependent Director$314,023
- Mr. Garen BohlinIndependent Director$339,023
- Dr. John FallonIndependent Director$328,023
- Dr. John FreundIndependent Director$339,023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 55
- Environment
- 37
- Social
- 87
- Governance
- 40
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Collegium Pharmaceutical Inc has several strengths that contribute to its success in the market. These include:
Weaknesses
- Despite Collegium Pharmaceutical Inc's strengths, it also faces certain weaknesses that pose challenges to its growth and competitiveness:
Opportunities
- Collegium Pharmaceutical Inc can capitalize on various opportunities to further expand its market presence and profitability:
Threats
- Collegium Pharmaceutical Inc faces certain threats that may hinder its growth and profitability:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.